article
Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments
Growing evidence reveals that using single immunotherapies to treat oncological…
Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.